The estimated Net Worth of Wayne Pisano is at least $1.06 Milion dollars as of 22 December 2022. Mr. Pisano owns over 20,000 units of Provention Bio stock worth over $711,880 and over the last 6 years he sold PRVB stock worth over $102,485. In addition, he makes $249,324 as Independent Chairman of the Board at Provention Bio.
Wayne has made over 4 trades of the Provention Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of PRVB stock worth $52,000 on 22 December 2022.
The largest trade he's ever made was exercising 20,000 units of Provention Bio stock on 22 December 2022 worth over $52,000. On average, Wayne trades about 3,280 units every 102 days since 2018. As of 22 December 2022 he still owns at least 28,498 units of Provention Bio stock.
You can see the complete history of Mr. Pisano stock trades at the bottom of the page.
Wayne F. Pisano serves as Independent Chairman of the Board of the Company. He also serves on the board of directors of Immunovaccine Inc., a biopharmaceutical company, since October 2011, and Oncolytics, Inc., a biotechnology company, since May 2013. Mr. Pisano served as president and CEO of VaxInnate, a biotechnology company, from January 2012 until November 2016. Prior to VaxInnate, Mr. Pisano was at Sanofi Pasteur from 1997 to 2011 and was President and CEO there from 2007 until his retirement in 2011. He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. Mr. Pisano’s depth of experience across the spectrum of commercial operations, public immunization policies and pipeline development make him a valuable member of our board of directors.
As the Independent Chairman of the Board of Provention Bio, the total compensation of Wayne Pisano at Provention Bio is $249,324. There are 12 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
Wayne Pisano is 65, he's been the Independent Chairman of the Board of Provention Bio since 2019. There are 2 older and 14 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
Wayne's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski oraz Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: